U019 Reducing Rural Health Disparities in Skin Cancer
DESCRIPTION
Rural areas face unique challenges regarding skin cancer management, such as a higher prevalence of skin cancers, lack of specialists and specialized treatment centers, long travel distance to receive care, lack of public transportation, and socioeconomic disparities. The impact on outcomes may include a delay in diagnosis, higher stage and diagnosis, diminished access to treatment and trial opportunities, and increased mortality rates. Potential tools and solutions to reduce health disparities will be discussed, including mobile clinics, community outreach, utilization of diagnostic and prognostic tools, and telehealth.
LEARNING OBJECTIVES
Identify scalable strategies to improve access to dermatologic care in rural and underserved populations, including teledermatology and primary care collaboration.
Better understand the epidemiology of skin cancer in rural areas through examples found in Kansas and the impact of placing a dermatology provider in a previously underserved area.
Better understand the necessity of collaborative care in bridging the gap between urban and rural health systems in dermatology deserts.
SCHEDULE
3:30 PM
Welcome
Sancy A. Leachman, MD, PhD, FAAD, Robert T. Brodell, MD, FAAD
3:35 PM
Rural Skin Cancer Epidemiology: Lessons from Garden City, KS
Brandon Richard Litzner, MD, FAAD
3:45 PM
Rural Dermatology and Access to Care: Scalable Lessons from New Mexico
John R. Durkin, MD, FAAD
4:00 PM
Delivering Mobile Dermatology to Rural Communities
Amy Snow, PA-C
4:15 PM
Panel Roundtable Discussion “Vision for the future: What are the most urgent and low-hanging opportunities and how do we best fill those gaps?”
DIRECTOR
Sancy A. Leachman, MD, PhD, FAAD
CO-DIRECTOR
Robert T. Brodell, MD, FAAD
University of Mississippi Medical Center
SPEAKERS
John R. Durkin, MD, FAAD
University of New Mexico
Brandon Richard Litzner, MD, FAAD
Amy Snow, PA-C
DISCLOSURES
Robert T. Brodell, MD, FAAD
Amgen – Consultant (1099 relationship)(Honoraria); Corrona, Inc. – Investigator(Grants/Research Funding); Eli Lilly – Investigator(Grants/Research Funding); Novartis Pharmaceuticals Corp. – Investigator(Grants/Research Funding); Regeneron – Consultant (1099 relationship)(Honoraria); Sanofi – Investigator(Grants/Research Funding); VeraDermics Inc. – Stockholder(Stock);
John R. Durkin, MD, FAAD
CorEvitas – Investigator(Grants/Research Funding); Eli Lilly – Advisory Board(Honoraria); Guidepoint Global, LLC – Independent Contractor(Fees); Incyte Corporation – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Leo Pharma – Advisory Board(Honoraria); Pfizer Inc. – Investigator(Grants/Research Funding); Regeneron Pharmaceuticals Inc – Investigator(Grants/Research Funding), Speaker(Honoraria); Sanofi – Advisory Board(Honoraria), Investigator(Grants/Research Funding);
Sancy A. Leachman, MD, PhD, FAAD
Castle Biosciences, Inc – Investigator(No Compensation Received); Merck & Co., Inc – Investigator(No Compensation Received); OrLucent, Inc. – Advisory Board(Honoraria); Pathology Watch – Advisory Board(No Compensation Received), Investigator(Grants/Research Funding); SkinBit Inc – Employee (w-2 relationship)(Salary);
Brandon Richard Litzner, MD, FAAD
No financial relationships exist with ineligible companies.
Amy Snow, PA-C
No financial relationships exist with ineligible companies.